Unicycive(US:UNCY) Globenewswireยท2025-10-08 14:45Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 14, 2025 [4]. Group 1: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [6]. - Specific deficiencies in cGMP compliance were identified at a third-party manufacturing vendor, which were not disclosed prior to the FDA's findings [7]. Group 2: Stock Price Impact - Following the announcement of deficiencies on June 10, 2025, Unicycive's stock price fell by $3.68 per share, a decrease of 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Legal Process and Participation - The lead plaintiff in the class action is the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [9]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9].